Clariant : UBS adjusts its price target

(CercleFinance.com) - UBS highlights the increase in margin forecasts, but considers that there are few signs of recovery in the short term.
The analyst confirms his buy recommendation on the stock, but adjusts his price target to E16 (from E17).

'Margins should improve from now on, but signs of recovery are limited in the short term' says UBS.

For the full year 2024, reported EBITDA margin should improve to around 16%, up 100 basis points on the previous estimate of around 15%. The Group also expects stable to low single-digit sales growth in local currency.

For 2025, Clariant expects to achieve an EBITDA margin of 17% to 18% and a free cash flow conversion rate of around 40% at the targeted level.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.